Clinical trials: Intermittent Claudication
Peripheral Artery Disease
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
This is a prospective, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System in subjects with post-balloon angioplasty (post-PTA) dissection(s) type(s) A…
- Trial name
- TOBA II (NCT02522884)
- Testing
- Tack Endovascular System
- Where
- 39 sites in United States, Austria and 1 more
- Volunteers
- 213 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Peripheral Arterial Disease
Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System.
- Trial name
- TOBA III (NCT02802306)
- Testing
- Tack Endovascular System
- Where
- 17 sites in Austria, Belgium and 2 more
- Volunteers
- 201 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Peripheral Artery Disease (PAD); Intermittent Claudication
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
This study is designed to determine whether LLG783 displays the clinical safety and efficacy profile, after multiple i.v. doses, to support further development in patients with PAD and intermittent claudication.
- Trial name
- PAD PoC (NCT03194776)
- Testing
- LLG783
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Lumbar Spinal Stenosis, Intermittent Claudication
Investigating Superion™ In Spinal Stenosis
The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffering from at least 6 months of…
- Trial name
- NCT00692276
- Testing
- Superion™ Interspinous Spacer, X-STOP® IPD® Device
- Where
- 32 sites in United States
- Volunteers
- 391 people
- Sponsor
- Boston Scientific Corporation
Peripheral Artery Disease, Peripheral Vascular Disease
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Collect confirmatory evidence of the safety and effectiveness of the Balloon LIFESTREAM™ Stent Graft for the treatment of stenoses and occlusion in the iliac arteries.
- Conditions
- Peripheral Artery Disease, Peripheral Vascular Disease, Arterial Occlusive Disease
- Trial name
- BOLSTER (NCT02228564)
- Testing
- Percutaneous transluminal angioplasty (PTA), LIFESTREAM™ covered stent
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 155 people
- Sponsor
- C. R. Bard
Peripheral Vascular Disease, Intermittent Claudication
Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication
The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market.
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Walking, Difficulty, Critical Limb Ischemia
- Trial name
- FlowOx (NCT04100681)
- Testing
- Active FlowOx™
- Where
- 5 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Otivio AS
Peripheral Arterial Disease, Claudication
Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
The Phoenix Post-Approval Registry is a prospective, multi-center, single arm registry sponsored by Volcano Corporation to evaluate the short and long term performance and clinical outcomes of the Phoenix Atherectomy System.
- Conditions
- Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
- Trial name
- NCT02475200
- Testing
- Atherectomy
- Where
- 5 sites in United States
- Volunteers
- 500 people
- Sponsor
- Volcano Corporation
Peripheral Arterial Disease
"Unifuzol®" in Patients With Peripheral Arterial Disease
The present study is a multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating atherosclerosis of the lower extremities.
- Trial name
- NCT03861416
- Testing
- L-arginine 1.4% 500 ml
- Where
- 19 sites in Russia
- Volunteers
- 360 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Peripheral Artery Disease, Claudication
Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries
The primary objective of this study is to prove the superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter for angioplasty for femoropopliteal artery lesions when compared to non-coated balloons at six months…
- Conditions
- Peripheral Artery Disease, Claudication, Atherosclerosis, Arteriosclerosis
- Trial name
- RANGER-SFA (NCT02013193)
- Testing
- Ranger DCB, uncoated PTA balloon
- Where
- 11 sites in Austria, France and 1 more
- Volunteers
- 105 people
- Sponsor
- Hemoteq AG
Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease
Evaluation of the GORE® VIABAHN® BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX)
The primary objective of the VBX13-05 clinical study is to evaluate the safety and efficacy of VIABAHN BX for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or…
- Conditions
- Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease, Peripheral Arterial Disease
- Trial name
- NCT01961167
- Testing
- Stenting of common and/or external iliacs
- Where
- New Zealand
- Volunteers
- 27 people
- Sponsor
- W.L.Gore & Associates
Superficial Femoral Artery Lesions, Atherosclerosis of Femoral Artery
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
This is an initial evaluation of the 480 Biomedical Bioresorbable Scaffold System for the treatment of subjects with de novo native superficial femoral artery lesions.
- Trial name
- STANCE (NCT01403077)
- Testing
- 480 Biomedical Bioresorbable Scaffold System
- Where
- 6 sites in Australia, Austria and 2 more
- Volunteers
- 46 people
- Sponsor
- 480 Biomedical
Peripheral Arterial Disease, Intermittent Claudication
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Vascular Diseases, Cardiovascular Diseases
- Trial name
- SPRINT (NCT02097082)
- Testing
- STANZA Drug-eluting resorbable Scaffold
- Where
- 9 sites in Austria, Germany and 2 more
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- 480 Biomedical
Peripheral Arterial Disease, Intermittent Claudication
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon…
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Atherosclerosis of Femoral Artery
- Trial name
- ENTRAP (NCT03271710)
- Testing
- peripheral balloon angioplasty
- Where
- 9 sites in Belgium, Germany
- Volunteers
- 113 people
- Sponsor
- Contego Medical, Inc.
Peripheral Arterial Disease, Claudication
Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)
The purpose of the study is to evaluate the intermediate and long-term effectiveness of stand-alone atherectomy treatment of peripheral arterial disease in the legs.
- Conditions
- Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
- Trial name
- NCT00883246
- Testing
- SilverHawk & TurboHawk Peripheral Plaque Excision System
- Volunteers
- 800 people
- Sponsor
- Medtronic Endovascular
Peripheral Arterial Disease, Claudication
Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease
The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon…
- Trial name
- DEFINITIVE AR (NCT01366482)
- Testing
- Cotavance Drug-Eluting Balloon, TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon
- Where
- Belgium
- Volunteers
- 121 people
- Sponsor
- Medtronic Endovascular
Intermittent Claudication, Peripheral Artery Disease
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and…
- Trial name
- NCT01131013
- Testing
- 375 mg CK-2017357, 500 mg CK-2017357
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- Cytokinetics
Intermittent Claudication
Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of…
- Trial name
- NCT03864666
- Testing
- Cilostazol 100 mg, PMR 200 mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Peripheral Artery Disease
Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries
The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.
- Trial name
- NCT02953496
- Testing
- vonapanitase
- Where
- United States
- Sponsor
- Proteon Therapeutics
Atherosclerosis, Peripheral Artery Disease
The ABSORB BTK (Below The Knee) Clinical Investigation
The purpose of the ABSORB BTK Clinical Investigation is to evaluate the safety and efficacy of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) in subjects with critical limb ischemia (CLI) following…
- Conditions
- Atherosclerosis, Peripheral Artery Disease, Peripheral Vascular Disease, PAD
- Trial name
- NCT01341340
- Testing
- Everolimus Eluting BVS
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Abbott Medical Devices